FDA Clocks REBYOTA Review: Patent Extension for Gut Drug Secured
Published Date: 7/2/2025
Notice
Summary
The FDA has officially set the review period for REBYOTA, a new human biological product, so its patent can be extended. This means the company behind REBYOTA gets more time to protect their invention and potentially earn more money. Anyone interested in drug patents or new treatments should keep an eye on this important timing update!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in